JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.22 4.27

Buy Sell

Overview

Share price change

24h

Current

Min

1.1400000000000001

Max

1.25

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+310.08% upside

Dividends
By Dow Jones
Next Earnings	3 mar 2026

Market Stats
By TradingEconomics
Market Cap	16M 142M
Previous open	-3.05
Previous close	1.22

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 lut 2026, 23:52 UTC

Acquisitions, Mergers, Takeovers

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 lut 2026, 23:52 UTC

Acquisitions, Mergers, Takeovers

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 lut 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 lut 2026, 23:38 UTC

Market Talk

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 lut 2026, 23:28 UTC

Market Talk

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 lut 2026, 23:23 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 lut 2026, 22:57 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 lut 2026, 22:08 UTC

Market Talk

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 lut 2026, 21:51 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 lut 2026, 21:49 UTC

Earnings

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 lut 2026, 21:39 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:36 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 lut 2026, 21:34 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 lut 2026, 21:23 UTC

Earnings

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 lut 2026, 21:19 UTC

Earnings

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 lut 2026, 21:17 UTC

Earnings

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 lut 2026, 21:17 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:10 UTC

Earnings

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 lut 2026, 21:08 UTC

Earnings

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 lut 2026, 21:07 UTC

Earnings

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Net $608.7M >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Rev $1.41B >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 lut 2026, 21:05 UTC

Earnings

Palantir Technologies 4Q EPS 24c >PLTR

2 lut 2026, 20:40 UTC

Market Talk

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

310.08% upside

12 Months Forecast

Average 4.88 USD 310.08%

High 8 USD

Low 2 USD

Based on 6 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.